Trials / Recruiting
RecruitingNCT05961592
R-2487 in Patients With Rheumatoid Arthritis
A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- Sponsor
- Rise Therapeutics LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-2487 DP | Probiotic |
Timeline
- Start date
- 2023-10-19
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
- First posted
- 2023-07-27
- Last updated
- 2025-09-23
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05961592. Inclusion in this directory is not an endorsement.